Showing 3801-3810 of 4902 results for "".
Melanoma Treatment Landscape Evolves
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-treatment-landscape-evolves/21314/The first agent to target the PD-1 pathway, pembrolizumab may prolong life expectancy in some patients.Analyzing Risk Factors for Subsequent Primary Melanomas
https://practicaldermatology.com/topics/skin-cancer-photoprotection/analyzing-risk-factors-for-subsequent-primary-melanomas/21429/SPF Recommendations: Should They Change?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/spf-recommendations-should-they-change/21475/What is the minimum SPF dermatologists should be recommending to their patients?Get More of the Patients You Want
https://practicaldermatology.com/topics/practice-management/get-more-of-the-patients-you-want/20520/How to use micro-targeted digital marketing to grow your practice.Contemporary African-American Hair Care Practices
https://practicaldermatology.com/topics/practice-management/contemporary-african-american-hair-care-practices/21176/As trends and sensibilities regarding hair practices shift, it is important for physicians to understand the needs of African-American patients in order to appropriately discuss healthy hair habits.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20671/Are We All Clear?
https://practicaldermatology.com/topics/psoriasis/are-we-all-clear/20725/Understanding the safety of biologics for psoriasis in real-world settings.Lead Psoriasis Patients Along the Path to Clearance
https://practicaldermatology.com/topics/psoriasis/PD0209_01-php/22873/With so many effective therapies now available, dermatologists must be prepared to guide their patients to the right treatment for their specific presentation.Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical manAssessing Dystrophic Nails: Finding the Cause
https://practicaldermatology.com/topics/general-topics/assessing-dystrophic-nails-finding-the-cause/21397/A podiatrist offers a unique perspective on the causes of dystrophic toenails.